Revenue Growth - Total revenue increased by 17% to $12.1 million, driven by platform revenue growth[4][5] - Platform revenue grew 76% to $4.0 million, with Annual Recurring Revenue (ARR) up 82% to $16.6 million[5][6] - Total revenue for Q1 2024 was $12,115,672, a 17.1% increase from $10,342,426 in Q1 2023[21] Profitability Metrics - Gross profit increased by 36%, with total gross margin improving 630 basis points to 45.2%[5][8] - Adjusted EBITDA reached a company record of $961,000, a 71.8% increase from the prior-year quarter[5][9] - Adjusted EBITDA for Q1 2024 was $960,740, a 71.8% increase from $559,382 in Q1 2023[15] - Gross profit for Q1 2024 was $5,481,932, a 36.1% increase from $4,027,273 in Q1 2023[21] Customer and Transaction Metrics - Transaction revenue was $8.2 million, with 1,426 active customers, a slight increase from 1,417 in the prior-year quarter[7] - Active customer accounts are defined as the sum of total customers per month divided by the number of months in the period, with customers having at least one transaction per month[12] - B2B ARR increased by 27.9% to $11.65 million, while B2C ARR reached $4.9 million[11] - Annual Recurring Revenue (ARR) is calculated as the annualized value of monthly subscriptions, multiplied by twelve for B2C ARR[13] Operating Expenses and Net Income - Total operating expenses increased by 38.5% to $5.4 million, primarily due to acquisitions[8] - Net income was $76,000, compared to $237,000 in the prior-year quarter[9] - Net income for Q1 2024 was $76,301, a 67.8% decrease from $236,842 in Q1 2023[15] - Net income (loss) for the nine months ended March 31, 2024, was $(965,370), compared to $195,877 in the same period in 2023[23] Cash Flow and Financial Position - Quarterly cash flow from operations exceeded $2 million, a company quarterly record[5] - Cash and cash equivalents as of March 31, 2024, were $4,221,424, a decrease from $13,545,333 as of June 30, 2023[19] - Accounts receivable as of March 31, 2024, were $7,323,379, an increase from $6,153,063 as of June 30, 2023[19] - Total assets as of March 31, 2024, were $40,803,199, an increase from $21,834,727 as of June 30, 2023[19] - Total liabilities as of March 31, 2024, were $26,674,940, an increase from $14,504,240 as of June 30, 2023[19] - Net cash provided by operating activities for the nine months ended March 31, 2024, was $1,589,791, down from $1,872,356 in the same period in 2023[23] - Net cash used in investing activities for the nine months ended March 31, 2024, was $(10,081,507), primarily due to acquisitions of Resolute and Scite[23] - Net cash used in financing activities for the nine months ended March 31, 2024, was $(836,984), including common stock repurchases of $(522,024)[23] - Cash and cash equivalents decreased by $9,323,909 to $4,221,424 at the end of March 31, 2024, from $13,545,333 at the beginning of the period[23] Depreciation, Amortization, and Other Expenses - Depreciation and amortization expenses increased to $525,267 for the nine months ended March 31, 2024, from $30,486 in the same period in 2023[23] - Fair value of vested restricted common stock increased to $1,603,820 for the nine months ended March 31, 2024, from $925,550 in the same period in 2023[23] - Accounts receivable decreased by $739,883 for the nine months ended March 31, 2024, compared to a decrease of $1,545,695 in the same period in 2023[23] - Deferred revenue increased by $768,347 for the nine months ended March 31, 2024, compared to an increase of $986,044 in the same period in 2023[23] - Cash paid for income taxes increased to $82,049 for the nine months ended March 31, 2024, from $5,543 in the same period in 2023[23] Product Launches - The company launched two new product offerings: Technology Landscape and Clinical Trial Landscape[3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter ...

Research Solutions, Inc. (NASDAQ:RSSS) Q2 2024 Earnings Conference Call February 8, 2024 5:00 PM ET Company Participants John Beisler - Three Part Advisors, Investor Relations Roy Olivier - President & Chief Executive Officer William Nurthen - Chief Financial Officer Conference Call Participants Allen Klee - Maxim Group Operator Good day and welcome to the Research Solutions, Inc. Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now lik ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charte ...

Research Solutions, Inc. (NASDAQ:RSSS) Q1 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants John Beisler - Three Part Advisors, Investor Relations Roy Olivier - Chief Executive Officer and President William Nurthen - Chief Financial Officer Conference Call Participants Richard Baldry - ROTH Capital Allen Klee - Maxim Group Operator Thank you for standing by. This is the conference operator. Welcome to the Research Solutions Inc. First Quarter 2024 Earnings Conference Call. As a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (State or ...

Research Solutions, Inc. (NASDAQ:RSSS) Q4 2023 Earnings Call Transcript September 13, 2023 5:00 PM ET Company Participants Steven Hooser - Investor Relations Roy W. Olivier - President and Chief Executive Officer Bill Nurthen - Chief Financial Officer Conference Call Participants Richard Baldry - Roth Capital Allen Klee - Maxim Group Peter Rabover - Artko Capital Operator Good afternoon, and welcome to the Research Solutions Fourth Quarter 2023 Earnings Conference Call. All participants will be in listen-on ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) N ...

Research Solutions, Inc. (NASDAQ:RSSS) Q3 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants John Beisler – Investor Relations Roy W. Olivier – President and Chief Executive Officer Bill Nurthen – Chief Financial Officer Conference Call Participants Allen Klee – Maxim Operator Good afternoon everyone and thank you for participating in today’s conference call to discuss Research Solutions’ Financial and Operating Results for its Fiscal Third Year Ended March 31, 2023. As a reminder, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File No. 001-39256 RESEARCH SOLUTIONS, INC. (Exact name of registrant as specified in its charter ...